Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

University of Chinese Academy Sciences

Status and phase

Unknown

Phase 2

Conditions

Brain Metastases

Non-small Cell Lung Cancer

Treatments

Drug: Icotinib

Study type

Interventional

Funder types

Other

Identifiers

NCT01688713

ZhejiangCH-LCBM-1202

Details and patient eligibility

About

Brain metastases, a common complication,occur in 25-40% of patients with non-small cell lung cancer (NSCLC). Whole-brain radiation therapy(WBRT) and Stereotactic Radiosurgery (SRS) are important approaches to the treatment of brain metastases from NSCLC. Known to us, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC, especially for EGFR mutation patients. However, due to the lower concentration of tyrosine kinase inhibitors (TKIs) in the cerebrospinal fluid and its inevitable emergence of drug resistance, brain metastases will be refractory or resistant to standard-dose EGFR inhibitors. Icotinib is one agent of EGFR-TKIs. The previous studies have shown that the Icotinib conventional dose (125mg, TID) is far from reached its maximum tolerable dose. It is a challenge whether the further dose escalation of Icotinib will enhance its concentration in cerebrospinal fluid and thereby improve its therapeutic effect. Here the investigators examine the therapeutic effect and side-effect of double dose of Icitinib in treating patients with brain metastases from NSCLC who have suffered from the failure of conventional dose treatment.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histological or cytologic diagnosis of NSCLC
Patients with disease progression after local treatment(WBRT and/or SRS) combined with Icotinib treatment.
Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment(WBRT and/or SRS) combined with Icotinib treatment.
ECOG performance status 0-2
Doctors consider the patients will not benefit from local treatment(WBRT and/or SRS)
Expected survival of greater than 3 months
Age: 18-75 years
The patients with key organs maintenance of basic function: Hemoglobin ≥ 9g/dL, White Blood Cell ≥ 3×109/L, Neutrophil count ≥ 1.5×109/L, platelets ≥ 80×109/L, total bilirubin < 1.5 times of the upper normal values, Alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 of the upper normal values, the serum creatinine < 1.5 times of the upper normal values
Signed informed consent document on file.

Exclusion criteria

Brain metastasis without local treatment before
Patients without the treatment of Icotinib before or the therapeutic time less than 3 months
More than 3 extracranial organs have metastatic lesions
The patient with other type malignant tumors before
The patient with fertility capacity, but without contraceptive application